The Bone Metastasis Market is seeing RANK ligand inhibitor segment grow in bone metastasis treatment commanding approximately 30-33% market share as RANK ligand inhibitors represent effective treatment for preventing bone complications improving survival rates by 75%, reducing bone pain by 80%, and preventing osteolysis by 78% creating substantial RANK ligand inhibitor...